Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report

The risk of abnormal bleeding with serotonin reuptake inhibitors has been known, but there is insufficient evidence base to guide pharmacological treatment of anxiety in patients with underlying haematological conditions. The following case report is about a 50-year-old female with generalized anxie...

Full description

Saved in:
Bibliographic Details
Main Authors: Mir Mazhar, Tariq Hassan, Tariq Munshi
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Case Reports in Psychiatry
Online Access:http://dx.doi.org/10.1155/2013/572630
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546187015618560
author Mir Mazhar
Tariq Hassan
Tariq Munshi
author_facet Mir Mazhar
Tariq Hassan
Tariq Munshi
author_sort Mir Mazhar
collection DOAJ
description The risk of abnormal bleeding with serotonin reuptake inhibitors has been known, but there is insufficient evidence base to guide pharmacological treatment of anxiety in patients with underlying haematological conditions. The following case report is about a 50-year-old female with generalized anxiety disorder, social phobia, obsessive compulsive disorder, and alcohol abuse where pharmacological treatment of anxiety symptoms has been difficult as it would lead to bruising due to the patient’s underlying qualitative platelet dysfunction. Treatment with venlafaxine, citalopram, escitalopram, and clomipramine resulted in improvement and anxiety symptoms, as well as reduction in alcohol use, but pharmacological treatment has to be discontinued because of bruising and hematomas. In view of an active substance use disorder, benzodiazepines were avoided as a treatment option. The patient’s anxiety symptoms and comorbid alcohol abuse responded well to pharmacological treatment with buspirone which gradually titrated up to a dose of 30 mg BID. Patient was followed for around a six-month period while she was on buspirone before being discharged to family doctor’s care. Buspirone is unlikely to have a significant effect on platelet serotonin transponder and could be an effective alternative for pharmacological treatment of anxiety in patients with a bleeding diathesis.
format Article
id doaj-art-3785b09f32524b759df1c3964db8facf
institution Kabale University
issn 2090-682X
2090-6838
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Case Reports in Psychiatry
spelling doaj-art-3785b09f32524b759df1c3964db8facf2025-02-03T07:23:35ZengWileyCase Reports in Psychiatry2090-682X2090-68382013-01-01201310.1155/2013/572630572630Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case ReportMir Mazhar0Tariq Hassan1Tariq Munshi2Department of Psychiatry, Queen’s University, Kingston, ON, K7L 7X3, CanadaDepartment of Psychiatry, Queen’s University, Kingston, ON, K7L 7X3, CanadaDepartment of Psychiatry, Queen’s University, Kingston, ON, K7L 7X3, CanadaThe risk of abnormal bleeding with serotonin reuptake inhibitors has been known, but there is insufficient evidence base to guide pharmacological treatment of anxiety in patients with underlying haematological conditions. The following case report is about a 50-year-old female with generalized anxiety disorder, social phobia, obsessive compulsive disorder, and alcohol abuse where pharmacological treatment of anxiety symptoms has been difficult as it would lead to bruising due to the patient’s underlying qualitative platelet dysfunction. Treatment with venlafaxine, citalopram, escitalopram, and clomipramine resulted in improvement and anxiety symptoms, as well as reduction in alcohol use, but pharmacological treatment has to be discontinued because of bruising and hematomas. In view of an active substance use disorder, benzodiazepines were avoided as a treatment option. The patient’s anxiety symptoms and comorbid alcohol abuse responded well to pharmacological treatment with buspirone which gradually titrated up to a dose of 30 mg BID. Patient was followed for around a six-month period while she was on buspirone before being discharged to family doctor’s care. Buspirone is unlikely to have a significant effect on platelet serotonin transponder and could be an effective alternative for pharmacological treatment of anxiety in patients with a bleeding diathesis.http://dx.doi.org/10.1155/2013/572630
spellingShingle Mir Mazhar
Tariq Hassan
Tariq Munshi
Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
Case Reports in Psychiatry
title Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
title_full Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
title_fullStr Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
title_full_unstemmed Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
title_short Treatment of Anxiety Disorders and Comorbid Alcohol Abuse with Buspirone in a Patient with Antidepressant-Induced Platelet Dysfunction: A Case Report
title_sort treatment of anxiety disorders and comorbid alcohol abuse with buspirone in a patient with antidepressant induced platelet dysfunction a case report
url http://dx.doi.org/10.1155/2013/572630
work_keys_str_mv AT mirmazhar treatmentofanxietydisordersandcomorbidalcoholabusewithbuspironeinapatientwithantidepressantinducedplateletdysfunctionacasereport
AT tariqhassan treatmentofanxietydisordersandcomorbidalcoholabusewithbuspironeinapatientwithantidepressantinducedplateletdysfunctionacasereport
AT tariqmunshi treatmentofanxietydisordersandcomorbidalcoholabusewithbuspironeinapatientwithantidepressantinducedplateletdysfunctionacasereport